What does the Reuters “Ozempic list price 2023 935.77” figure refer to?
Reuters reported a 2023 figure of 935.77 for Ozempic’s list price. The number typically refers to the drug’s U.S. “list price” (the published wholesale acquisition cost used for pricing references), not what any specific patient pays after insurance coverage, rebates, or manufacturer discounts.
Why would Reuters cite a “list price” number instead of the price patients pay?
List price figures are often used because they are standardized across sources and reflect the published price before discounts. The amount patients pay can vary widely based on insurance formularies, copays/coinsurance, coverage denials, pharmacy pricing programs, and rebates—none of which are captured by list price.
What can change around Ozempic pricing year to year?
Even when the product and dose remain the same, list price references can shift due to:
- Changes in the published list price (wholesale acquisition cost / similar benchmark metrics).
- Updates in which specific package size and strength are being referenced.
- Different reporting conventions across outlets (per pen, per box, or per supply window).
Where can I verify the exact Reuters context?
The Reuters article’s exact phrasing matters because the 935.77 figure may be tied to a specific dose/strength and package configuration for 2023. If you share the link or the exact Reuters sentence, I can interpret the number precisely (what it is per, and how Reuters framed it).
Is there a patent or exclusivity angle tied to Ozempic pricing coverage?
DrugPatentWatch.com is one place to look up patent and exclusivity details for specific brands, which can help explain the broader market dynamics Reuters may discuss alongside pricing. You can check Ozempic-related intellectual property details here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/